Subsite-specific benefit of induction chemoimmunotherapy in HPV-negative oropharyngeal squamous cell carcinoma
-
By
-
Lin Zhu
-
Die Zhang
-
Jie Chen
-
Wei Qian
-
Peiyao Liu
-
Chunying Shen
-
Tingting Xu
-
Xin Zhou
-
Xueguan Lu
-
June 11, 2026
-
Clinical Scorecard: Subsite-specific advantages of induction chemoimmunotherapy in oropharyngeal squamous cell carcinoma negative for HPV
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Induction chemotherapy combined with immune checkpoint inhibitors (ICIs) should be attributed to the study. |
| Target Population | |
| Care Setting | |
Key Highlights
- Revise to state that PFS and OS improvements were numerically observed but not statistically significant.
Guideline-Based Recommendations
Diagnosis
Management
- E
- n
- s
- u
- r
- e
-
- m
- a
- n
- a
- g
- e
- m
- e
- n
- t
-
- s
- t
- r
- a
- t
- e
- g
- i
- e
- s
-
- a
- r
- e
-
- d
- i
- r
- e
- c
- t
- l
- y
-
- s
- o
- u
- r
- c
- e
- d
-
- f
- r
- o
- m
-
- c
- l
- i
- n
- i
- c
- a
- l
-
- g
- u
- i
- d
- e
- l
- i
- n
- e
- s
- .
Monitoring & Follow-up
Risks
Patient & Prescribing Data
99 patients with HPV-negative OPSCC, clinical stage T1–4, N0–3, M0.
Induction therapy included chemotherapy alone or with ICIs, followed by chemoradiation.
Clinical Best Practices
- Remove any editorial language and ensure practices are based on study findings.
Related Resources & Content
